Sobi

rare **strength**

August, 2021

Forward-looking statements

In order to utilise the 'Safe Harbor' provisions of the United States Private Securities Litigation Reform Act of 1995, Swedish Orphan Biovitrum AB (publ) is providing the following cautionary statement. This presentation contains forward-looking statements with respect to the financial condition, results of operations and businesses of Swedish Orphan Biovitrum AB (publ), By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, the loss or expiration of patents, marketing exclusivity or trade marks; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability claims; the impact of any failure by third parties to supply materials or services; the risk of delay to new product launches; the difficulties of obtaining and maintaining governmental approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new products do not perform as we expect; and the risk of environmental liabilities.

Sobi is an industry-leading rare disease specialist

- Innovative treatments in Haematology, Immunology and Specialty Care
- Strong suite of pre-market assets and portfolio of on-market products
- Growth driven by robust pipeline, ramp up of launch products, internationalisation, and strategic M&A
- Strong commercial platform with global presence

	Portfolio Assets	
	Haematology	**Immunology**
Pre-market	Efanesoctocog alfa (BIVV001)[1] – haemophilia A Pegcetacoplan[2] – PNH	Emapalumab – sHLH Emapalumab – aGF Nirsevimab[3] – RSV Pegcetacoplan – ALS SEL-212[4] – chronic refractory gout
On-market	Elocta® – haemophilia A Alprolix® – haemophilia B Doptelet® – ITP, CLD	Kineret® – several indications Synagis® – RSV Gamifant® – pHLH

1. Developed and, if approved, will be commercialised in collaboration with Sanofi.
2. In collaboration with Apellis
3. Financial interest only, in collaboration with AstraZeneca.
4. Strategic licensing agreement with Selecta.

M&A and partnerships a key driver building the company



BIVV001 is developed and, if approved, will be commercialised in collaboration with Sanofi.
Nirsevimab is being developed by AZ and commercialised by Sanofi. Sobi has an option to the rights to 50% of the profits and losses of the product in the US.

Q2 confirms transformation and delivery of the strategy



Grow the core

- **Haematology is back to growth**

  Doptelet key growth driver

  Haemophilia back to growth

Late-stage pipeline

- Submitted anakinra for COVID-19 indication
- Pipeline progress: pegcetacoplan, efanesoctocog alfa and nirsevimab

Go global

- Preparations for launches in Russia and continue to build organisation in China and Japan

Back to double-digit revenue growth – highlights in Q2

- **Solid double-digit topline growth in Q2 driven by key products**
  - Doptelet® growth, 42 per cent at CER
  - Kineret® growth, 14 per cent at CER
  - Gamifant® growth, 46 per cent at CER
- **Continued patient growth**
  - Patient growth:
    - 3 per cent for Elocta®
    - 16 per cent for Alprolix®
- **Improved market conditions – solid profitability**
  - Q2 2021 revenue of SEK 3,211 M and EBITA margin of 29 per cent
  - Increased investments in R&D and SG&A
- **Outlook unchanged**

Pipeline progress

- **Kineret (anakinra)** – SAVE-MORE demonstrated positive results in management of COVID-19 pneumonia
  - Submitted to the EMA in July for treatment of COVID-19 in adult patients with pneumonia at risk of severe respiratory failure
  - Submitted to MHRA (UK)
  - Emergency Use Authorisation will be explored with FDA
- **Efanesoctocog alfa (BIVV001)** – first patient dosed in paediatric study on the back of enrolment of the adult study
- **Pegcetacoplan** – positive topline results from the phase 3 PRINCE study in treatment-naïve patients with paroxysmal nocturnal haemoglobinuria (PNH)
- **Nirsevimab**
  - MELODY phase 3 trial met primary endpoint of reduction in the incidence of medically attended lower respiratory tract infections caused by respiratory syncytial virus in healthy infants (35w or more gestation)
  - MEDLEY phase 2/3 trial showed positive topline results, similar safety and tolerability profile compared to palivizumab in preterm infants or those with chronic lung disease or congenital heart disease

Key near term catalysts for our late-stage pipeline

	Indication	Program timeline	Potential next milestone
Efanesoctocog alfa (BIVV001)	Haemophilia A		Top-line data H1 2022 (adults), H1 2023 (paed)
Pegcetacoplan	PNH		Potential EU approval H2 2021
	CAD		Phase 3 study to be initiated H2 2021
	IC-MPGN & C3G		Phase 3 study to be initiated H2 2021
	ALS		Full enrolment H2 2021
	HSCT-TMA		Phase 2 study to initiated H2 2021
Emapalumab	Rheumatologic HLH		Initiate phase 3 study H2 2021, read out H2 2022
	Primary HLH (RoW)		Potential approval China H2
SEL-212	CRG		Read out H2 2022
Nirsevimab*	RSV Prevention		Full data 2022



PNH: Paroxysmal Nocturnal Haemoglobinuria, CAD: Cold Agglutin Disease, IC-MPGN & C3G: Immune complex membranoproliferative glomerulonephritis and C3 glomerulopathy, ALS: Amyotrophic lateral sclerosis, HSCT-TMA: Haematopoietic stem cell transplantation thrombotic microangiopathies, HLH: Hemophagocytic lymphohistiocytosis, CRG: Chronic refractory gout

* Nirsevimab is under the control of Sanofi / AZ, Sobi has a financial interest only

Financial outlook: leveraging R&D investments

	2021	Long-term
Sales	**SEK 14 – 15B**	**Continuous potential double-digit growth**
EBITA Margin	**30 – 35% of sales**	**Margin acceleration**

R&D	**13 – 15% of sales**	**13 – 15% of sales;
		Pipeline of late-stage assets to be brought to approval**
		• Investments in:
		  • SEL-212
		  • Pegcetacoplan across several indications
		  • Emapalumab indication expansion into GF and sHLH

SG&A	**Gradually increase throughout year**	**Realising the potential of launches on a global scale** • Continued investments in Doptelet and Gamifant • Launch of SEL-212, pegcetacoplan and efanesoctocog alfa/BIVV001 • Further investments in infrastructure in international markets

Conclusion

Grow the core – returned to growth, continued patient gain and strengthened market share

Deliver on late-stage pipeline and launches – further investments in our late-stage pipeline and preparing the organisation for potential launches in 2021 and 2022

Go global – seize opportunities as a large fraction of rare disease market is outside the US/EU

Reinvesting strong cash flow in growth – continued financial strength will support long-term growth through M&A

Swedish Orphan Biovitrum AB (publ)
SE-112 76 Stockholm • Sweden
www.sobi.com

sobi
rare **strength**